Connection

Co-Authors

This is a "connection" page, showing publications co-authored by VICTOR PRIETO and MICHAEL TETZLAFF.
Connection Strength

9.785
  1. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Mod Pathol. 2013 Sep; 26(9):1153-60.
    View in: PubMed
    Score: 0.465
  2. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
    View in: PubMed
    Score: 0.226
  3. Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. Arch Pathol Lab Med. 2021 12 01; 145(12):1505-1515.
    View in: PubMed
    Score: 0.212
  4. Perianal condylomata lata mimicking carcinoma. J Cutan Pathol. 2022 03; 49(3):209-214.
    View in: PubMed
    Score: 0.200
  5. Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. Per Med. 2020 09; 17(5):361-371.
    View in: PubMed
    Score: 0.192
  6. Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications. Am J Surg Pathol. 2019 12; 43(12):1701-1710.
    View in: PubMed
    Score: 0.184
  7. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.180
  8. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.
    View in: PubMed
    Score: 0.180
  9. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res. 2019 06 01; 25(11):3455-3467.
    View in: PubMed
    Score: 0.175
  10. Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations. Clin Cancer Res. 2019 02 15; 25(4):1280-1290.
    View in: PubMed
    Score: 0.172
  11. Post-radiation vascular lesions of the breast. J Cutan Pathol. 2019 Jan; 46(1):52-58.
    View in: PubMed
    Score: 0.171
  12. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868.
    View in: PubMed
    Score: 0.168
  13. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018 02 12; 6(1):14.
    View in: PubMed
    Score: 0.163
  14. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086.
    View in: PubMed
    Score: 0.159
  15. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079.
    View in: PubMed
    Score: 0.159
  16. Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. Clin Lab Med. 2017 09; 37(3):431-448.
    View in: PubMed
    Score: 0.158
  17. Living on the Edge: Diagnosing Sarcomatoid Melanoma Using Histopathologic Cues at the Edge of a Dedifferentiated Tumor: A Report of 2 Cases and Review of the Literature. Am J Dermatopathol. 2017 Aug; 39(8):593-598.
    View in: PubMed
    Score: 0.157
  18. Isolated Ectopic Cutaneous Atypical Meningioma of the Scalp: Another Mimicker of Primary Adnexal Tumor. Am J Dermatopathol. 2017 Jul; 39(7):545-547.
    View in: PubMed
    Score: 0.156
  19. Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall. Am J Dermatopathol. 2017 Jun; 39(6):468-470.
    View in: PubMed
    Score: 0.155
  20. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. Am J Dermatopathol. 2017 Feb; 39(2):121-129.
    View in: PubMed
    Score: 0.152
  21. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176.
    View in: PubMed
    Score: 0.150
  22. Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
    View in: PubMed
    Score: 0.150
  23. Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a case. J Cutan Pathol. 2016 Dec; 43(12):1155-1160.
    View in: PubMed
    Score: 0.148
  24. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016 09; 240(1):84-95.
    View in: PubMed
    Score: 0.147
  25. Prognostic Implication of Lymphovascular Invasion Detected by Double Immunostaining for D2-40 and MITF1 in Primary Cutaneous Melanoma. Am J Dermatopathol. 2016 Jul; 38(7):484-91.
    View in: PubMed
    Score: 0.146
  26. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5553-5563.
    View in: PubMed
    Score: 0.144
  27. Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas. J Cutan Pathol. 2016 Aug; 43(8):722-4.
    View in: PubMed
    Score: 0.144
  28. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors. Hum Pathol. 2016 07; 53:73-81.
    View in: PubMed
    Score: 0.143
  29. Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs. JAMA Ophthalmol. 2015 Oct; 133(10):1109-16.
    View in: PubMed
    Score: 0.138
  30. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med. 2015 Sep; 4(9):1440-7.
    View in: PubMed
    Score: 0.136
  31. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.134
  32. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.133
  33. Emerging clinical applications of selected biomarkers in melanoma. Clin Cosmet Investig Dermatol. 2015; 8:35-46.
    View in: PubMed
    Score: 0.132
  34. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.
    View in: PubMed
    Score: 0.131
  35. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61.
    View in: PubMed
    Score: 0.127
  36. Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. Mod Pathol. 2014 Nov; 27(11):1468-78.
    View in: PubMed
    Score: 0.125
  37. Pigmented extramammary Paget disease of the thigh mimicking a melanocytic tumor: report of a case and review of the literature. J Cutan Pathol. 2014 Jun; 41(6):529-35.
    View in: PubMed
    Score: 0.125
  38. Ambiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analyses. Am J Surg Pathol. 2013 Dec; 37(12):1783-96.
    View in: PubMed
    Score: 0.122
  39. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84.
    View in: PubMed
    Score: 0.119
  40. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8.
    View in: PubMed
    Score: 0.115
  41. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg. 2012 Dec; 31(4):267-73.
    View in: PubMed
    Score: 0.114
  42. Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. J Cutan Pathol. 2012 Sep; 39(9):866-71.
    View in: PubMed
    Score: 0.111
  43. The utility of ATF3 in distinguishing cutaneous squamous cell carcinoma among other cutaneous epithelial neoplasms. J Cutan Pathol. 2012 Aug; 39(8):762-8.
    View in: PubMed
    Score: 0.110
  44. Phenotypic switch in mycosis fungoides: A tertiary cancer center experience. Hum Pathol. 2023 Dec; 142:27-33.
    View in: PubMed
    Score: 0.061
  45. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells. J Cutan Pathol. 2023 Jul; 50(7):661-673.
    View in: PubMed
    Score: 0.059
  46. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.
    View in: PubMed
    Score: 0.058
  47. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders? Virchows Arch. 2021 Aug; 479(2):377-383.
    View in: PubMed
    Score: 0.050
  48. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. J Cutan Pathol. 2021 May; 48(5):674-679.
    View in: PubMed
    Score: 0.050
  49. Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma. Ophthalmic Plast Reconstr Surg. 2021 Jan-Feb 01; 37(1):e9-e13.
    View in: PubMed
    Score: 0.050
  50. Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition. J Cutan Pathol. 2021 Apr; 48(4):526-534.
    View in: PubMed
    Score: 0.049
  51. Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. J Cutan Pathol. 2021 Apr; 48(4):547-557.
    View in: PubMed
    Score: 0.049
  52. Prognostic significance of acral lentiginous histologic type in T1 melanoma. Mod Pathol. 2021 03; 34(3):572-583.
    View in: PubMed
    Score: 0.048
  53. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. J Cutan Pathol. 2020 Oct; 47(10):954-959.
    View in: PubMed
    Score: 0.048
  54. TERT amplification but not activation of canonical Wnt/?-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Mod Pathol. 2020 10; 33(10):2067-2074.
    View in: PubMed
    Score: 0.048
  55. Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data? Am J Dermatopathol. 2020 May; 42(5):337-342.
    View in: PubMed
    Score: 0.047
  56. BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. Am J Dermatopathol. 2020 May; 42(5):313-321.
    View in: PubMed
    Score: 0.047
  57. T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. J Invest Dermatol. 2020 11; 140(11):2146-2156.e4.
    View in: PubMed
    Score: 0.047
  58. Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. J Cutan Pathol. 2020 May; 47(5):490-493.
    View in: PubMed
    Score: 0.047
  59. Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers (Basel). 2019 Dec 16; 11(12).
    View in: PubMed
    Score: 0.046
  60. Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. Cancers (Basel). 2019 Nov 02; 11(11).
    View in: PubMed
    Score: 0.046
  61. Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593.
    View in: PubMed
    Score: 0.046
  62. Unusual cutaneous metastatic carcinoma. Ann Diagn Pathol. 2019 Dec; 43:151399.
    View in: PubMed
    Score: 0.045
  63. Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. J Cutan Pathol. 2020 Jan; 47(1):36-46.
    View in: PubMed
    Score: 0.045
  64. Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes. Am J Surg Pathol. 2019 07; 43(7):907-919.
    View in: PubMed
    Score: 0.045
  65. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers (Basel). 2019 May 29; 11(6).
    View in: PubMed
    Score: 0.045
  66. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019 Sep; 46(9):627-636.
    View in: PubMed
    Score: 0.044
  67. Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series. Am J Dermatopathol. 2019 Mar; 41(3):167-179.
    View in: PubMed
    Score: 0.044
  68. Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. J Cutan Pathol. 2019 Feb; 46(2):152-158.
    View in: PubMed
    Score: 0.043
  69. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
    View in: PubMed
    Score: 0.043
  70. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.043
  71. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835.
    View in: PubMed
    Score: 0.043
  72. Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma. Hum Pathol. 2019 02; 84:270-274.
    View in: PubMed
    Score: 0.043
  73. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.043
  74. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct; 45(10):786-790.
    View in: PubMed
    Score: 0.042
  75. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. J Cutan Pathol. 2018 Oct; 45(10):764-773.
    View in: PubMed
    Score: 0.042
  76. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol. 2018 Jul; 45(7):545-549.
    View in: PubMed
    Score: 0.041
  77. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol. 2018 Jul; 45(7):539-544.
    View in: PubMed
    Score: 0.041
  78. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol. 2018 Jul; 45(7):504-507.
    View in: PubMed
    Score: 0.041
  79. Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma. Hum Pathol. 2018 07; 77:98-107.
    View in: PubMed
    Score: 0.041
  80. Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers. Ann Diagn Pathol. 2018 Jun; 34:151-154.
    View in: PubMed
    Score: 0.041
  81. Coccidioidomycosis Involving Lungs and Skin: A Mimicker of Metastatic Disease. Am J Dermatopathol. 2018 Mar; 40(3):e41-e43.
    View in: PubMed
    Score: 0.041
  82. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. Int J Dermatol. 2019 Sep; 58(9):1045-1052.
    View in: PubMed
    Score: 0.040
  83. Differential expression of CCR4 in primary cutaneous gamma/delta (?/d) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. J Dermatol Sci. 2018 Jan; 89(1):88-91.
    View in: PubMed
    Score: 0.039
  84. Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy. Am J Dermatopathol. 2017 Aug; 39(8):e116-e118.
    View in: PubMed
    Score: 0.039
  85. Aberrant expression of FLI-1 in melanoma. J Cutan Pathol. 2017 Sep; 44(9):790-793.
    View in: PubMed
    Score: 0.039
  86. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions. Am J Dermatopathol. 2017 Jul; 39(7):504-507.
    View in: PubMed
    Score: 0.039
  87. Detection of Merkel Cell Polyoma Virus and Beta Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Acute Leukemia Treated With Stem Cell Transplant. Am J Dermatopathol. 2017 06; 39(6):489-491.
    View in: PubMed
    Score: 0.039
  88. Concomitant Cutaneous Langerhans Cell Hystiocytosis and Leukemia Cutis. Am J Dermatopathol. 2017 May; 39(5):388-392.
    View in: PubMed
    Score: 0.039
  89. Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.
    View in: PubMed
    Score: 0.038
  90. Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncoimmunology. 2017; 6(5):e1306618.
    View in: PubMed
    Score: 0.038
  91. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.038
  92. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res. 2017 02; 27(1):24-31.
    View in: PubMed
    Score: 0.038
  93. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (?d) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous ?d T-Cell Lymphomas. Am J Surg Pathol. 2017 Feb; 41(2):204-215.
    View in: PubMed
    Score: 0.038
  94. Primary Cutaneous Gamma-Delta (?/d) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. Am J Dermatopathol. 2016 10; 38(10):e147-9.
    View in: PubMed
    Score: 0.037
  95. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. Hum Pathol. 2017 01; 59:48-54.
    View in: PubMed
    Score: 0.037
  96. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 Dec; 43(12):1161-1166.
    View in: PubMed
    Score: 0.037
  97. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.036
  98. Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. Mod Pathol. 2016 08; 29(8):832-43.
    View in: PubMed
    Score: 0.036
  99. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016 Aug; 43(8):688-96.
    View in: PubMed
    Score: 0.036
  100. Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. J Clin Pathol. 2016 May; 69(5):382-90.
    View in: PubMed
    Score: 0.035
  101. Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. Ann Clin Lab Sci. 2016; 46(2):222-4.
    View in: PubMed
    Score: 0.035
  102. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016 Apr; 50:79-89.
    View in: PubMed
    Score: 0.035
  103. Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature. J Cutan Pathol. 2016 Mar; 43(3):252-7.
    View in: PubMed
    Score: 0.035
  104. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma. Am J Dermatopathol. 2015 Aug; 37(8):e96-9.
    View in: PubMed
    Score: 0.034
  105. Metastatic atypical fibroxanthoma: a series of 11 cases including with minimal and no subcutaneous involvement. Am J Dermatopathol. 2015 Jun; 37(6):455-61.
    View in: PubMed
    Score: 0.034
  106. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer. 2015 Jun 15; 121(12):1993-2003.
    View in: PubMed
    Score: 0.033
  107. HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. J Dermatol Sci. 2015 Mar; 77(3):150-5.
    View in: PubMed
    Score: 0.033
  108. Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. J Cutan Pathol. 2014 Nov; 41(11):846-52.
    View in: PubMed
    Score: 0.032
  109. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.032
  110. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies. Am J Surg Pathol. 2014 Aug; 38(8):1102-10.
    View in: PubMed
    Score: 0.032
  111. Primary orbital melanoma in association with cellular blue nevus. Digit J Ophthalmol. 2014; 20(3):35-40.
    View in: PubMed
    Score: 0.032
  112. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014 Nov 01; 20(21):5537-46.
    View in: PubMed
    Score: 0.031
  113. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014 Mar; 41(3):326-8.
    View in: PubMed
    Score: 0.031
  114. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.
    View in: PubMed
    Score: 0.030
  115. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol. 2014 Feb; 41(2):88-100.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.